Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma

Med Lett Drugs Ther. 2018 Jul 16;60(1551):e122-e123.
No abstract available

Keywords: Actemra; Rituxan; Yescarta; adverse effects; axicabtagene ciloleucel; corticosteroids; cyclophosphamide; dosage; doxorubicin; efficacy; lymphoma; prednisone; pregnancy; rituximab; safety; tisagenlecleucel; tocilizumab; vincristine.

MeSH terms

  • Antigens, CD19 / immunology
  • Antigens, CD19 / therapeutic use*
  • Biological Products
  • Disease-Free Survival
  • Drug Approval
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, B-Cell / drug therapy*
  • Receptors, Antigen, T-Cell / immunology
  • T-Lymphocytes / immunology*
  • United States
  • United States Food and Drug Administration

Substances

  • Antigens, CD19
  • Biological Products
  • Receptors, Antigen, T-Cell
  • axicabtagene ciloleucel